Supervised resistance exercise for women with ovarian cancer who have completed first-line treatment: a pragmatic study

被引:8
作者
Schofield, Christelle [1 ,5 ]
Newton, Robert U. [1 ,5 ]
Taaffe, Dennis R. [1 ,5 ]
Galvao, Daniel A. [1 ,5 ]
Cohen, Paul A. [2 ,3 ,5 ]
Meniawy, Tarek M. [2 ,3 ,4 ,5 ]
Peddle-McIntyre, Carolyn J. [1 ,5 ]
机构
[1] Edith Cowan Univ, Exercise Med Res Inst, Joondalup, WA, Australia
[2] Univ Western Australia, Sch Med, Crawley, WA, Australia
[3] St John God Hosp, Subiaco, WA, Australia
[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia
[5] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA, Australia
关键词
Ovarian cancer; Resistance exercise; Muscle mass; Muscle strength; Physical function; FEMALE PELVIC FLOOR; QUALITY-OF-LIFE; OLDER-ADULTS; ACTIVITY BEHAVIORS; PHYSICAL-ACTIVITY; CONTROLLED-TRIAL; CHEMOTHERAPY; SURVIVORS; MYOSTEATOSIS; SARCOPENIA;
D O I
10.1007/s00520-023-07754-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectivesIn ovarian cancer (OC), suboptimal muscle morphology (i.e., low muscle mass and density) is associated with poor clinical outcomes, yet little is known about the effect of interventions aimed at improving these measures. We investigated the effect of resistance exercise after first-line treatment on muscle mass and density, muscle strength and physical function, health-related quality of life (QoL), and pelvic-floor function in advanced-stage OC survivors.MethodsFifteen OC survivors participated in supervised resistance exercise twice weekly for 12 weeks (in-clinic or by telehealth). Assessments included muscle mass and density (dual-energy X-ray absorptiometry, peripheral quantitative computed tomography), muscle strength (1-repetition maximum [1RM] chest press, 5RM leg press, handgrip strength), physical function (400-m walk, timed up-and-go [TUG]), QoL (QLQ-C30 questionnaire), and self-reported pelvic floor function (Australian Pelvic Floor Questionnaire).ResultsThe median age was 64 (range 33-72) years, 10 women underwent neoadjuvant chemotherapy and five underwent adjuvant chemotherapy. All participants completed the intervention (median attendance = 92%; range 79-100%). Post-intervention improvements were observed for whole-body lean mass (1.0 +/- 1.4 kg, p = 0.015), appendicular lean mass (0.6 +/- 0.9 kg, p = 0.013), muscle density (p = 0.011), upper and lower body strength (p <= 0.001), 400-m walk (p = 0.001), TUG (p = 0.005), and social and cognitive QoL domains (p = 0.002 and 0.007), with no change to pelvic floor symptoms (p > 0.05).ConclusionIn this study, supervised resistance exercise effectively improved muscle mass and density, muscle strength, and physical functioning without deleterious effects on the pelvic floor. Considering the prognostic value of these outcomes, larger studies are needed to confirm the benefits of resistance exercise in OC supportive care.
引用
收藏
页数:12
相关论文
共 50 条
[21]   Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? [J].
Petignat, Patrick ;
du Bois, Andreas ;
Bruchim, Ilan ;
Fink, Daniel ;
Provencher, Diane M. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 62 (02) :137-147
[22]   Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer [J].
Ngoi, Natalie Y. L. ;
Syn, Nicholas L. X. ;
Goh, Robby M. ;
Goh, Boon Cher ;
Huang, Ruby Yun-Ju ;
Soon, Yu Yang ;
James, Elizabeth ;
Cook, Adrian ;
Clamp, Andrew ;
Tan, David S. P. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (02)
[23]   Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns) [J].
Beesley, Vanessa L. ;
Ross, Tanya L. ;
King, Madeleine T. ;
Campbell, Rachel ;
Nagle, Christina M. ;
Obermair, Andreas ;
Grant, Peter ;
DeFazio, Anna ;
Webb, Penelope M. ;
Friedlander, Michael L. .
GYNECOLOGIC ONCOLOGY, 2022, 164 (02) :437-445
[24]   Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer - A systematic review with melaanalyses [J].
Elit, Laurie ;
Oliver, Thomas K. ;
Covens, Allan ;
Kwon, Janice ;
Fung, Michael -Kee Fung ;
Hirte, Holger W. ;
Oza, Amit M. .
CANCER, 2007, 109 (04) :692-702
[25]   Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women [J].
Pampanini, Valentina ;
Wagner, Magdalena ;
Asadi-Azarbaijani, Babak ;
Oskam, Irma C. ;
Sheikhi, Mona ;
Sjodin, Marcus O. D. ;
Lindberg, Johan ;
Hovatta, Outi ;
Sahlin, Lena ;
Bjorvang, Richelle D. ;
Otala, Marjut ;
Damdimopoulou, Pauliina ;
Jahnukainen, Kirsi .
HUMAN REPRODUCTION, 2019, 34 (09) :1674-1685
[26]   Current post-surgical treatment strategies in first-line ovarian cancer [J].
Ouali, Kaissa ;
Michels, Judith ;
Blanc-Durand, Felix ;
Leary, Alexandra ;
Kfoury, Maria ;
Genestie, Catherine ;
Morice, Philippe ;
Zaccarini, Francois ;
Scherrier, Stephanie ;
Gouy, Sebastien ;
Maulard, Amandine ;
Pautier, Patricia .
BULLETIN DU CANCER, 2024, 111 (03) :267-276
[27]   Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort [J].
Conic, Irena ;
Nedovic, Bojan ;
Stojnev, Slavica ;
Todorovska, Ilinka ;
Dimitrijevic, Aleksandra ;
Krstic, Miljan ;
Djordjevic, Ivana ;
Djordjevic, Biljana .
MEDICINA-LITHUANIA, 2022, 58 (05)
[28]   The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer [J].
Bookman, M. A. .
ANNALS OF ONCOLOGY, 2010, 21 :211-217
[29]   Effects of a clinician referral and exercise program for men who have completed active treatment for prostate cancer: A multicenter cluster randomized controlled trial (ENGAGE) [J].
Livingston, Patricia M. ;
Craike, Melinda J. ;
Salmon, Jo ;
Courneya, Kerry S. ;
Gaskin, Cadeyrn J. ;
Fraser, Steve F. ;
Mohebbi, Mohammadreza ;
Broadbent, Suzanne ;
Botti, Mari ;
Kent, Bridie .
CANCER, 2015, 121 (15) :2646-2654
[30]   Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study [J].
Belpomme, D ;
Krakowski, I ;
Beauduin, M ;
Petit, T ;
Canon, JL ;
Janssens, J ;
Gauthier, S ;
De Pauw, A ;
Moreau, V ;
Kayitalire, L .
GYNECOLOGIC ONCOLOGY, 2003, 91 (01) :32-38